Second Decision Point. In the event that, pursuant to Section 1.6(a), ▇▇▇▇▇▇▇▇ fails to terminate this Agreement in accordance with Section 10.4(d) on or before the First Decision Point, ▇▇▇▇▇▇▇▇ shall have the right to opt-out of the commercialization process for the First Female Product on or before the Second Decision Point. In the event that ▇▇▇▇▇▇▇▇ determines on or before the Second Decision Point to opt-out of the commercialization process, ▇▇▇▇▇▇▇▇ shall terminate this Agreement pursuant to Section 10.4(d). In the event that ▇▇▇▇▇▇▇▇ fails to terminate this Agreement pursuant to Section 10.4(d) on or before Second Decision Point, ▇▇▇▇▇▇▇▇ shall be deemed to have elected to continue commercializing Female Product(s) (such election, the “Launch Decision”), and ▇▇▇▇▇▇▇▇ shall make the Second Development Completion Payment to Palomar in the amount set forth in Section 6.1(d)(i) on or before the Second Development Completion Payment Date.
Appears in 2 contracts
Sources: Non Exclusive Patent License (Cutera Inc), Development and License Agreement (Palomar Medical Technologies Inc)
Second Decision Point. In the event that, pursuant to Section 1.6(a), ▇▇▇▇▇▇▇▇ fails to terminate this Agreement in accordance with Section 10.4(d) on or before the First Decision Point, ▇▇▇▇▇▇▇▇ shall have the right to opt-out of the commercialization process for the First Female Product on or before the Second Decision Point. In the event that ▇▇▇▇▇▇▇▇ determines on or before the Second Decision Point to opt-out of the commercialization process, ▇▇▇▇▇▇▇▇ shall terminate this Agreement pursuant to Section 10.4(d). In the event that ▇▇▇▇▇▇▇▇ fails to terminate this Agreement pursuant to Section 10.4(d) on or before Second Decision Point, ▇▇▇▇▇▇▇▇ shall be deemed to have elected to continue commercializing Female Product(s) (such election, the “Launch Decision”), and ▇▇▇▇▇▇▇▇ shall make the Second Development Completion Payment to Palomar in the amount set forth in Section 6.1(d)(i) on or before the Second Development Completion Payment Date.. ARTICLE III [Intentionally Omitted] ARTICLE IV License Grants 4.1
Appears in 1 contract
Sources: Development and License Agreement (Palomar Medical Technologies Inc)
Second Decision Point. In the event that, pursuant to Section 1.6(a), ▇G▇▇▇▇▇▇▇ fails to terminate this Agreement in accordance with Section 10.4(d) on or before the First Decision Point, ▇G▇▇▇▇▇▇▇ shall have the right to opt-out of the commercialization process for the First Female Product on or before the Second Decision Point. In the event that ▇G▇▇▇▇▇▇▇ determines on or before the Second Decision Point to opt-out of the commercialization process, ▇G▇▇▇▇▇▇▇ shall terminate this Agreement pursuant to Section 10.4(d). In the event that ▇G▇▇▇▇▇▇▇ fails to terminate this Agreement pursuant to Section 10.4(d) on or before Second Decision Point, ▇G▇▇▇▇▇▇▇ shall be deemed to have elected to continue commercializing Female Product(s) (such election, the “Launch Decision”), and ▇G▇▇▇▇▇▇▇ shall make the Second Development Completion Payment to Palomar in the amount set forth in Section 6.1(d)(i) on or before the Second Development Completion Payment Date.
Appears in 1 contract